Comparison
Lixisenatide vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
320367-13-3
2179963-22-7
Molecular weight
4858.5 g/mol
4727 g/mol
Half-life
3 h
168 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
5
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2